MPR Weekly Dose
198 episodes - English - Latest episode: 8 days ago - ★★★★★ - 3 ratingsEach week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test
April 12, 2024 14:36 - 11 minutes - 15.7 MBAsthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.
MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection
April 05, 2024 15:43 - 11 minutes - 16 MBFirst prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.
MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning
March 29, 2024 15:44 - 13 minutes - 18.6 MBPreexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.
MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System
March 22, 2024 14:04 - 14 minutes - 19.4 MBNasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.
MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results
March 15, 2024 15:54 - 13 minutes - 18.1 MBWeight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results
MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva
March 08, 2024 16:00 - 13 minutes - 18.7 MBOver-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved.
MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled
March 01, 2024 15:49 - 17 minutes - 23.4 MBFDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.
MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning
February 23, 2024 15:38 - 13 minutes - 18.7 MBFirst treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose.
MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter
February 16, 2024 15:38 - 14 minutes - 19.4 MBFDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared.
MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete’s Foot Spray Recalled
February 09, 2024 16:57 - 14 minutes - 20.1 MBCombination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled.
MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops
February 02, 2024 15:39 - 12 minutes - 17.2 MBBiogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products
MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler
January 26, 2024 15:31 - 12 minutes - 17.8 MBT-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved
MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended
January 19, 2024 15:44 - 13 minutes - 18.6 MBGene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension
MPR Weekly Dose 186 — Diabetes Tx Suicidal Ideation Link Examined; Topical Molluscum Contagiosum Tx; Superpotent IV Bags Recalled; Syphilis Treatment Update; Menstrual Blood to Measure HbA1c
January 12, 2024 14:49 - 14 minutes - 20.6 MBResearchers examine link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on the penicillin shortage; newly cleared test measures HbA1c from menstrual blood.
MPR Weekly Dose 185 — Best Diets for 2024; Counterfeit Ozempic; Myasthenia Gravis Tx Approved; Herpes False Positive Test Results; Promethazine Hydrochloride Safety Concerns
January 05, 2024 15:47 - 12 minutes - 17.1 MBAn expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.
MPR Weekly Dose 184 — Gel Approved for EB Wounds; 21-Valent Pneumococcal Vaccine; Prescription Game Therapy for ADHD; HIV-Protecting Vaginal Insert; Multiple Food Allergy Drug
December 21, 2023 22:32 - 16 minutes - 22.5 MBTopical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug
MPR Weekly Dose 183 — Updated Diabetes Guidelines; Novel Blood Collection Device; Postpartum Depression Tx; Male Birth Control Study; Approval Sought for Psychoactive Drug
December 15, 2023 16:36 - 13 minutes - 18.6 MBThe ADA release their new guidance for the management of diabetes 2024; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.
MPR Weekly Dose Podcast #182 — Novel Weight Loss Tx; Safety Risks for Compounded Semaglutide; Fabhalta Approved for PNH; At-Home Insemination Kit; Sleep Apnea Device Cleared
December 08, 2023 17:15 - 14 minutes - 20.6 MBNovel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.
MPR Weekly Dose Podcast #181 — Serious Reactions to Seizure Treatments; Desmoid Tumor Tx; Secondary CAR T-Cell Malignancies; Immunosuppressive Recall; CPAP Machine Issues
December 01, 2023 15:41 - 14 minutes - 20.1 MBSafety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.
MPR Weekly Dose Podcast #180 — Chikungunya Vaccine; Amazon FDA Warning; At-Home STD Test; Lymphoma Drug Withdrawn; Antimicrobial Catheter Lock Solution for CRBSI
November 17, 2023 14:16 - 13 minutes - 19.2 MBFirst chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved.
MPR Weekly Dose Podcast #179 — Weight Management Tx; Levemir Discontinued; Renal Denervation System Approved; Gene Therapy Fasted Tracked; Hidden Drugs in Glucose Supplement
November 10, 2023 17:51 - 12 minutes - 17.5 MBNew weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement.
MPR Weekly Dose Podcast #178 — FDA Flags Eye Drops; Ped Alert for COVID-19 Vaccine; Novel Heartburn Tx; Biosimilar to Stelara Approved; Anti-Fentanyl Monoclonal Antibody
November 03, 2023 14:45 - 11 minutes - 16.3 MBFDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked.
MPR Weekly Dose Podcast 177 — Penbraya Approved; COVID-19 Therapy Shelf-Life Extended; New Formulation for IBD Tx; Self-Admin FluMist; Nonopioid Combo for Postop Pain
October 27, 2023 14:13 - 11 minutes - 15.9 MBNew pentavalent meningococcal vaccine approved; Gohibic’s shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain.
MPR Weekly Dose 176 — Novel MDD Tx; Panel Votes Against ALS Therapy; Preservation-Free Iyuzeh; RSV Vaccine Recommended for During Pregnancy; Investigative Tx Shows Promise in FCS
September 29, 2023 12:50 - 13 minutes - 18.8 MBFDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.
MPR Weekly Dose 175 — Xacduro Now Available; Epinephrine Application Denied; Flu Vaccine Efficacy; New Dosing Regimen for Talicia; Change to Generic Tacrolimus
September 22, 2023 16:30 - 13 minutes - 18 MBBacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic.
MPR Weekly Dose 174 — Updated COVID-19 Vaccines; Px Drop for Dry Eye Disease; Crohn Disease Tx Trial; Lotronex Update; FDA Cracks Down on Unapproved Eye Products
September 15, 2023 21:56 - 12 minutes - 16.8 MBThe FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.
MPR Weekly Dose Podcast #173 — Talking vaccines with Dr. Abdul-Mutakabbir
September 06, 2023 14:46 - 30 minutes - 41.6 MBWith fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine.
MPR Weekly Dose 171 — Vaccine Guidance for Flu Season; PrEP Recommendation; Maternal RSV Vaccine; Latest on Updated COVID Vaccine; CHAPLE Disease Tx Approved
August 25, 2023 14:11 - 18 minutes - 25.1 MBNew vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease.
MPR Weekly Dose 170 — Warning Alert for Tests; Arexy Available for Older Adults; Sohonos and Hezato Kit Approved; Statement on GLP-1 Use Before Endoscopy
August 18, 2023 13:59 - 15 minutes - 21.4 MBFDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy.
MPR Weekly Dose 169 — New Postpartum Depression Tx; Generic Naloxone Spray; Weight Management Drug Shows Heart Benefits; CDC Recommends RSV Vaccine; SAD Tx
August 11, 2023 14:21 - 14 minutes - 19.4 MBOral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.
MPR Weekly Dose 168 — Prescription stimulant shortage; Electronic transfer of controlled substances; Oral contraceptive recall; Ebola vaccine; OTC opioid overdose approval
August 04, 2023 13:18 - 11 minutes - 16.4 MBDrug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment.
MPR Weekly Dose 167 — Molluscum contagiosum Tx approved; Xdemvy and Balfaxar approved; Weight loss drug in short supply; Cervical pessary assessed for reducing preterm birth
July 28, 2023 13:38 - 12 minutes - 17.7 MBSingle-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth.
MPR Weekly Dose 166 — Potential Alzheimer drug may slow disease; RSV Tx for neonates, toddlers; Veklury and Brenzavvy approvals expanded; Blood test false negatives
July 21, 2023 13:21 - 15 minutes - 20.8 MBStudy supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.
MPR Weekly Dose 165 — OTC Birth Control Pill; Heart Tx Gains Expanded Approval; Gavreto Indication Withdrawn; Albuterol Inhaler Recall; Paclitaxel-Coated Device Analysis
July 14, 2023 14:08 - 11 minutes - 15.4 MBFirst over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices.
MPR Weekly Dose 164 — Approvals for Alopecia, Generalized Myasthenia Gravis, and Type 1 Diabetes; Colonoscopy Prep; FDA Deny Application for Pre-Cirrhotic Fibrosis Tx
June 30, 2023 13:59 - 13 minutes - 17.9 MBNew approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH.
MPR Weekly Dose 163 — COVID-19 Vaccine Authorization Revoked; Injectafer Approved; Lumryz Single Dose for Narcolepsy; Vowst for C. Difficile; Approval for CMV Disease Prevention
June 08, 2023 22:20 - 13 minutes - 18.4 MBFDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.
MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx
June 02, 2023 14:36 - 12 minutes - 17.6 MBNew vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.
MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
May 26, 2023 14:16 - 15 minutes - 21.4 MBFirst oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled.
MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child’s Smart Thermometer Recalled
May 19, 2023 16:48 - 11 minutes - 16.4 MBFDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled.
MPR Weekly Dose 159 — OTC Birth Control Pill Switch; First Tx for Agitation Associated With Dementia; Fabry Disease Treatment; Farxiga Approval Expanded; Contaminated COVID-19 Tests
May 12, 2023 15:07 - 13 minutes - 18.1 MBPanel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests.
MPR Weekly Dose 158 — Early Alzheimer Treatment; First RSV Vaccine; Narcolepsy Tx; Toilet Seat That Monitors Health; FDA Ammonia Warning
May 05, 2023 14:51 - 12 minutes - 16.5 MBInvestigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And the FDA warns of energy boosting over-the-counter inhalants.
MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert
April 28, 2023 14:24 - 10 minutes - 15 MBLarge recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.
MPR Weekly Dose 156 — Bivalent COVID-19 Vaccines; Vote on Agitation With Alzheimer Dementia Tx; Descheduled Drug; Migraine Tx Expansion; Restless Legs Syndrome Device
April 21, 2023 15:25 - 11 minutes - 16 MBUpdates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome.
MPR Weekly Dose 155 — Knee Shock Absorber; Opioid Label Updates; Imbruvica Indications Withdrawn; Patch for Excessive Sweating; Polyclonal Tx for Flu
April 14, 2023 15:12 - 13 minutes - 17.9 MBImplantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza.
MPR Weekly Dose 154 — Novel COVID-19 Tx Granted EUA; Makena Withdrawn; Infant Supine Sleep System; Padcev Plus Keytruda Approved; Opioid Mail-Back Envelopes, Respiratory Depression Detection Device
April 07, 2023 14:20 - 15 minutes - 20.9 MBTreatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New Padcev plus Keytruda indication; Mail-back system for unused opioids; Opioid overdose prevention device approved
MPR Weekly Dose 153 — Diabetes Drugs Discontinued; Trial Results for Schizophrenia Tx; Intranasal Spray Assessed for SAD; High-concentration Humira biosimilar; Inspire Therapy Indication Expanded
March 24, 2023 13:51 - 11 minutes - 15.7 MBTwo diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms with an investigational Tx; Positive results for investigational Social Anxiety Disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome
MPR Weekly Dose 152 — Booster Dose Authorized for Under 5s; Rapid STI Test; Rett Syndrome and Migraine Tx Approved; Panel Takes Vote for Polivy Combo
March 17, 2023 14:56 - 12 minutes - 17.1 MBCOVID-19 Booster dose authorized for those aged 6 months through 4 years; Rapid STI point-of-care test for women is cleared; Rett syndrome and migraine Tx Approved; and The Oncology Drugs Advisory Committee takes a vote on a drug combination treatment for diffuse large b-cell lymphoma.
MPR Weekly Dose 151 — Liver Injury Decline Tied to FDA Rule; Alzheimer Disease Tx Update; Bempedoic Acid in MACE; Blood Test Cleared for TBI Assessment; Mammography Regulatory Update.
March 10, 2023 15:46 - 12 minutes - 17.8 MBLimits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.
MPR Weekly Dose 150 — Kevzara, Skyclarys Approved; At-Home Combo COVID and Flu Test; Drug-Resistant Shigellosis on Rise; FDA Restrictions on Xylazine-Containing Products
March 03, 2023 15:15 - 13 minutes - 18.9 MBKevzara approved for polymyalgia rheumatica; Skyclarys approved for Friedreich ataxia; Emergency authorization granted to at-home COVID-19, flu test; Drug-resistant bacteria virus spiking in the US; FDA clamps down on unlawful xylazine imports.
MPR Weekly Dose 149 — Post-Exposure Molnupiravir Study; Filspari Approved; Treatment for Geographic Atrophy Secondary to AMD Approved; Personalized Melanoma Vaccine; RSV Maternal Vaccine
February 24, 2023 14:48 - 14 minutes - 19.7 MBResults from postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect from RSV complications in infants.